Comprehensive assessments should cover cognition, motor function, and biomarkers—such as CSF or blood-based α-synuclein seed amplification assays [57–59], AD biomarkers [53], and PET imaging including amyloid and tau PET (e.g., 18F-MK-6240) [60]. This evidence concerns the gene MAPT and amyloidosis.